share_log

HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Raises Price Target to $47

Benzinga ·  Oct 11, 2023 09:52

HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and raises the price target from $35 to $47.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment